Overview
In this program we will examine the evolving therapeutic landscape for squamous cell non-small cell lung cancer (NSCLC) treatment. The introduction of immune checkpoint inhibitors into treatment algorithms is the primary catalyst of new therapeutic options. We will review the completed and ongoing pivotal clinical trials that are contributing toward the development of new treatment paradigms for squamous NSCLC. We will also provide case examples that illustrate the decision-making process for practicing clinicians.
After viewing the program, attendees will be able:
- illustrate the rapid evolution in the therapeutic landscape of advanced squamous lung cancer.
- differentiate recently completed and ongoing clinical trials in advanced squamous lung cancer.
- demonstrate how changes in treatment algorithms affect the decision-making process for practicing oncologists.
David R. Gandara, MD
Professor of Medicine, Program Director, Thoracic Oncology Program, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center.
For any inquiries, please contact meetings@iaslc.org.
After viewing the program, attendees will be able:
- illustrate the rapid evolution in the therapeutic landscape of advanced squamous lung cancer.
- differentiate recently completed and ongoing clinical trials in advanced squamous lung cancer.
- demonstrate how changes in treatment algorithms affect the decision-making process for practicing oncologists.
David R. Gandara, MD
Professor of Medicine, Program Director, Thoracic Oncology Program, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center.
For any inquiries, please contact meetings@iaslc.org.